{"id":690481,"date":"2022-09-29T16:04:14","date_gmt":"2022-09-29T20:04:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\/"},"modified":"2022-09-29T16:04:14","modified_gmt":"2022-09-29T20:04:14","slug":"longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\/","title":{"rendered":"Longboard Pharmaceuticals to Participate in the Cantor Neurology &amp; Psychiatry Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, Sept.  29, 2022  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=odBXc2zzVmP-lsrP1r_Pj_LIjHGMveRtv_GG9yccFtHjyVLxI7tSoWLRrth4ICW591bXX1JwsxPQ9mw58DdTUqOXejbd6TRv8TbXBKIpZccchqHDeUyRfVXy2YQHmdYW\" rel=\"nofollow noopener\" target=\"_blank\">Longboard Pharmaceuticals, Inc.<\/a> (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Kevin Lind, Longboard\u2019s President &amp; CEO, will participate in a panel discussion at the Cantor Neurology &amp; Psychiatry Conference, which is taking place October 6-7, 2022, in San Francisco, CA.<\/p>\n<p align=\"justify\">\n        <strong>Presentation Details:<\/strong><br \/>\n        <br \/>\n        <strong>Panel Title:<\/strong> Next generation drugs, new targets and innovative approaches for high-unmet need epileptic disorders <br \/><strong>Date\/Time:<\/strong> October 6, 2022, at 4:20 PM ET (1:20 PM PT) in Track 2<br \/>Please note, this presentation will be available to registered conference attendees only. Please reach out to your Cantor representative for additional detail or to arrange a meeting with management.<\/p>\n<p align=\"justify\">\n        <strong>About Longboard Pharmaceuticals <\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=odBXc2zzVmP-lsrP1r_Pj_LIjHGMveRtv_GG9yccFtFij0n9Fppxv3_1je-Y8rh0ycchfFis45dxSJaNEVjIzqPA5gI6fIGEddUKeWQmEmvfjRMs33AZxJEwD3QmbYMd\" rel=\"nofollow noopener\" target=\"_blank\">Longboard Pharmaceuticals, Inc.<\/a>\u00a0is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard\u2019s small molecule product\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3VfTjBrbzvjJXIwr8HDAFxU9r1bHuD--s0IVeJc13sjQUSEmrYOjnDQQ88Xq4CN8Wzkfz4rbSUgPt-0hMciLmTK5bGJD23lgbQKFGhMdi8BgvbzC5iKrkzagxvCbqM5F\" rel=\"nofollow noopener\" target=\"_blank\">candidates<\/a>\u00a0are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. Longboard is also evaluating LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, in development for the potential treatment of multiple neurological diseases, and LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, in development for the potential treatment of central nervous system (CNS) diseases and disorders.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements <\/strong><br \/>\n        <br \/>Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Longboard\u2019s participation in the upcoming conference, Longboard\u2019s clinical and preclinical programs, ability to develop and deliver medicines, and focus. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard\u2019s expectations. Factors that could cause actual results to differ materially from those stated or implied by Longboard\u2019s forward-looking statements are disclosed in Longboard\u2019s filings with the Securities and Exchange Commission (SEC). These forward-looking statements represent Longboard\u2019s judgment as of the time of this release. Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NjE2MiM1MTc5NTQwIzIyMDYyNzA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YTVjN2RmMjAtMWRjNy00YjE0LWFhMTAtZGNlM2QzNDFiZTczLTEyMTc4MjM=\/tiny\/Longboard-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Corporate Contact:\r\nMegan E. Knight\r\nHead of Investor Relations\u00a0\r\nmknight@longboardpharma.com\r\nIR@longboardpharma.com\r\n619.592.9775<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) &#8212; Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Kevin Lind, Longboard\u2019s President &amp; CEO, will participate in a panel discussion at the Cantor Neurology &amp; Psychiatry Conference, which is taking place October 6-7, 2022, in San Francisco, CA. Presentation Details: Panel Title: Next generation drugs, new targets and innovative approaches for high-unmet need epileptic disorders Date\/Time: October 6, 2022, at 4:20 PM ET (1:20 PM PT) in Track 2Please note, this presentation will be available to registered conference attendees only. Please reach out to your Cantor representative for additional detail or to arrange a meeting with management. About Longboard &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Longboard Pharmaceuticals to Participate in the Cantor Neurology &amp; Psychiatry Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-690481","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Longboard Pharmaceuticals to Participate in the Cantor Neurology &amp; Psychiatry Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Longboard Pharmaceuticals to Participate in the Cantor Neurology &amp; Psychiatry Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) &#8212; Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Kevin Lind, Longboard\u2019s President &amp; CEO, will participate in a panel discussion at the Cantor Neurology &amp; Psychiatry Conference, which is taking place October 6-7, 2022, in San Francisco, CA. Presentation Details: Panel Title: Next generation drugs, new targets and innovative approaches for high-unmet need epileptic disorders Date\/Time: October 6, 2022, at 4:20 PM ET (1:20 PM PT) in Track 2Please note, this presentation will be available to registered conference attendees only. Please reach out to your Cantor representative for additional detail or to arrange a meeting with management. About Longboard &hellip; Continue reading &quot;Longboard Pharmaceuticals to Participate in the Cantor Neurology &amp; Psychiatry Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-29T20:04:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NjE2MiM1MTc5NTQwIzIyMDYyNzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Longboard Pharmaceuticals to Participate in the Cantor Neurology &amp; Psychiatry Conference\",\"datePublished\":\"2022-09-29T20:04:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\\\/\"},\"wordCount\":415,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NjE2MiM1MTc5NTQwIzIyMDYyNzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\\\/\",\"name\":\"Longboard Pharmaceuticals to Participate in the Cantor Neurology &amp; Psychiatry Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NjE2MiM1MTc5NTQwIzIyMDYyNzA=\",\"datePublished\":\"2022-09-29T20:04:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NjE2MiM1MTc5NTQwIzIyMDYyNzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NjE2MiM1MTc5NTQwIzIyMDYyNzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Longboard Pharmaceuticals to Participate in the Cantor Neurology &amp; Psychiatry Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Longboard Pharmaceuticals to Participate in the Cantor Neurology &amp; Psychiatry Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\/","og_locale":"en_US","og_type":"article","og_title":"Longboard Pharmaceuticals to Participate in the Cantor Neurology &amp; Psychiatry Conference - Market Newsdesk","og_description":"SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) &#8212; Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Kevin Lind, Longboard\u2019s President &amp; CEO, will participate in a panel discussion at the Cantor Neurology &amp; Psychiatry Conference, which is taking place October 6-7, 2022, in San Francisco, CA. Presentation Details: Panel Title: Next generation drugs, new targets and innovative approaches for high-unmet need epileptic disorders Date\/Time: October 6, 2022, at 4:20 PM ET (1:20 PM PT) in Track 2Please note, this presentation will be available to registered conference attendees only. Please reach out to your Cantor representative for additional detail or to arrange a meeting with management. About Longboard &hellip; Continue reading \"Longboard Pharmaceuticals to Participate in the Cantor Neurology &amp; Psychiatry Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-29T20:04:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NjE2MiM1MTc5NTQwIzIyMDYyNzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Longboard Pharmaceuticals to Participate in the Cantor Neurology &amp; Psychiatry Conference","datePublished":"2022-09-29T20:04:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\/"},"wordCount":415,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NjE2MiM1MTc5NTQwIzIyMDYyNzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\/","name":"Longboard Pharmaceuticals to Participate in the Cantor Neurology &amp; Psychiatry Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NjE2MiM1MTc5NTQwIzIyMDYyNzA=","datePublished":"2022-09-29T20:04:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NjE2MiM1MTc5NTQwIzIyMDYyNzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NjE2MiM1MTc5NTQwIzIyMDYyNzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longboard-pharmaceuticals-to-participate-in-the-cantor-neurology-psychiatry-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Longboard Pharmaceuticals to Participate in the Cantor Neurology &amp; Psychiatry Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690481","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=690481"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690481\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=690481"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=690481"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=690481"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}